{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:58:10Z","timestamp":1793861890878,"version":"4.6.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 01KG1508"],"award-info":[{"award-number":["FKZ 01KG1508"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.euroneuro.2018.11.1105","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T17:55:34Z","timestamp":1542909334000},"page":"32-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6125-1466","authenticated-orcid":false,"given":"Marc","family":"Krause","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4011-1189","authenticated-orcid":false,"given":"Maximilian","family":"Huhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bighelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Gutsmiedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.euroneuro.2018.11.1105_bib0001","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/10550490701389658","article-title":"Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia","volume":"16","author":"Akerele","year":"2007","journal-title":"Am. J. Addict."},{"issue":"8574","key":"10.1016\/j.euroneuro.2018.11.1105_bib0002","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0140-6736(87)92620-1","article-title":"Cannabis and schizophrenia a longitudinal study of Swedish conscripts","volume":"330","author":"Andr\u00e9asson","year":"1987","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.euroneuro.2018.11.1105_bib0003","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2018.11.1105_bib0004","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/JCP.0000000000000789","article-title":"Late reduction of cocaine cravings in a randomized, double-blind trial of aripiprazole vs perphenazine in schizophrenia and comorbid cocaine dependence","volume":"37","author":"Beresford","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2018.11.1105_bib0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00004850-199905030-00005","article-title":"A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial","volume":"14","author":"Berk","year":"1999","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2018.11.1105_bib0006","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/13651500009177999","article-title":"Risperidone compared to haloperidol in cannabis-induced psychotic disorder: a double blind randomized controlled trial","volume":"4","author":"Berk","year":"2000","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"2","key":"10.1016\/j.euroneuro.2018.11.1105_bib0007","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3736\/jcim20060204","article-title":"Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: clinical trial design and methodology","volume":"4","author":"Bian","year":"2006","journal-title":"Zhong Xi Yi Jie He Xue Bao"},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0008","doi-asserted-by":"crossref","unstructured":"Blows, W.T., 2016. Biological Basis of Mental Health, 3rd ed., 1 online resource .","DOI":"10.4324\/9781315707167"},{"issue":"1\u20132","key":"10.1016\/j.euroneuro.2018.11.1105_bib0009","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/15504263.2011.570118","article-title":"A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia","volume":"7","author":"Brunette","year":"2011","journal-title":"J. Dual Diagn."},{"issue":"2","key":"10.1016\/j.euroneuro.2018.11.1105_bib0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.euroneuro.2018.11.1105_bib0012","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"issue":"6","key":"10.1016\/j.euroneuro.2018.11.1105_bib0013","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"J. Gen. Intern. Med."},{"issue":"Suppl","key":"10.1016\/j.euroneuro.2018.11.1105_bib0014","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0920-9964(98)00161-3","article-title":"Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes","volume":"35","author":"Dixon","year":"1999","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.euroneuro.2018.11.1105_bib0015","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/sj.npp.1301207","article-title":"Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia","volume":"31","author":"D'Souza","year":"2006","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. College Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2018.11.1105_bib0016","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"Int. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.euroneuro.2018.11.1105_bib0017","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3109\/00952990.2013.861843","article-title":"Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis","volume":"40","author":"Farnia","year":"2014","journal-title":"Am. J. Drug Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.euroneuro.2018.11.1105_bib0018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0019","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.13m08838","article-title":"Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial","author":"Green","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2018.11.1105_bib0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.schres.2003.08.001","article-title":"First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol","volume":"66","author":"Green","year":"2004","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.euroneuro.2018.11.1105_bib0021","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/15622975.2015.1009163","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation","volume":"16","author":"Hasan","year":"2015","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0022","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"issue":"10","key":"10.1016\/j.euroneuro.2018.11.1105_bib0024","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.addbeh.2009.02.003","article-title":"Reprint of \"Treatment of cannabis use disorders in people with schizophrenia spectrum disorders \u2013 a systematic review\"","volume":"34","author":"Hjorthoj","year":"2009","journal-title":"Addict. Behav."},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","article-title":"Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990\u20132017: systematic review and meta-analysis","volume":"191","author":"Hunt","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0026","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Med."},{"issue":"10053","key":"10.1016\/j.euroneuro.2018.11.1105_bib0027","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(16)31460-X","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Kassebaum","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.11.1105_bib0028","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.euroneuro.2018.11.1105_bib0029","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/15504263.2012.647345","article-title":"The potential role of long-acting injectable antipsychotics in people with schizophrenia and comorbid substance use","volume":"8","author":"Koola","year":"2012","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2018.09.007","article-title":"Antipsychotic drugs for elderly patients with schizophrenia: a systematic review and meta-analysis","author":"Krause","year":"2018","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. College Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0031","article-title":"The next step in evidence-based treatment of schizophrenia. Individualising the care for important patient subgroups","volume":"2016","author":"Krause","year":"2016","journal-title":"Prospero"},{"issue":"6","key":"10.1016\/j.euroneuro.2018.11.1105_bib0032","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis","volume":"28","author":"Krause","year":"2018","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0033","doi-asserted-by":"crossref","DOI":"10.1007\/s00406-018-0869-3","article-title":"Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis","author":"Krause","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.euroneuro.2018.11.1105_bib0034","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"9896","key":"10.1016\/j.euroneuro.2018.11.1105_bib0035","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0036","article-title":"Which are the most important first-generation antipsychotic drugs? Survey of international schizophrenia experts: abstracts from the 5th biennial SIRS conference \u2013 poster abstracts","volume":"25","author":"Leucht","year":"2016","journal-title":"NPJ Schizophr."},{"issue":"10","key":"10.1016\/j.euroneuro.2018.11.1105_bib0037","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.euroneuro.2018.11.1105_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med."},{"issue":"12","key":"10.1016\/j.euroneuro.2018.11.1105_bib0039","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.euroneuro.2018.11.1105_bib0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/0269881114527357","article-title":"The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: an fMRI study","volume":"28","author":"Machielsen","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.euroneuro.2018.11.1105_bib0041","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s001270170038","article-title":"Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia","volume":"36","author":"Miller","year":"2001","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0042","doi-asserted-by":"crossref","unstructured":"Montada, L., Learner, M.J. (Eds.), 1998. Responses to Victimizations and Belief in a Just World. Plenum Press, New York, p. 278.","DOI":"10.1007\/978-1-4757-6418-5"},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0043","series-title":"Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014","year":"2014"},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2018.11.1105_bib0044","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.schres.2010.02.184","article-title":"Clozapine vs. risperidone for people with first episode schizophrenia and co-occurring cannabis use disorder","volume":"117","author":"Noordsy","year":"2010","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.euroneuro.2018.11.1105_bib0045","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"issue":"5","key":"10.1016\/j.euroneuro.2018.11.1105_bib0046","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2174\/1570159X11311050003","article-title":"The effectiveness of treatments for cocaine dependence in schizophrenic patients: a systematic review","volume":"11","author":"Sabioni","year":"2013","journal-title":"Curr. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2018.11.1105_bib0047","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Res. Synth. Methods"},{"issue":"6","key":"10.1016\/j.euroneuro.2018.11.1105_bib0048","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/01.nmd.0000165089.14736.bf","article-title":"Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol","volume":"193","author":"Sayers","year":"2005","journal-title":"J. Nerv. Ment. Dis."},{"issue":"3","key":"10.1016\/j.euroneuro.2018.11.1105_bib0049","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1521-0391.2014.12126.x","article-title":"Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study","volume":"23","author":"Schnell","year":"2014","journal-title":"Am. J. Addict."},{"issue":"3","key":"10.1016\/j.euroneuro.2018.11.1105_bib0050","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.psychres.2011.05.001","article-title":"Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes","volume":"188","author":"Sevy","year":"2011","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.euroneuro.2018.11.1105_bib0051","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2105\/AJPH.89.3.385","article-title":"Morbidity and mortality attributable to alcohol, tobacco, and illicit drug use in Canada","volume":"89","author":"Single","year":"1999","journal-title":"Am. J. Public Health"},{"issue":"11","key":"10.1016\/j.euroneuro.2018.11.1105_bib0052","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00023210-200822110-00002","article-title":"Pharmacological treatment of schizophrenia and co-occurring substance use disorders","volume":"22","author":"Smelson","year":"2008","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.euroneuro.2018.11.1105_bib0053","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/070674370204700710","article-title":"Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence","volume":"47","author":"Smelson","year":"2002","journal-title":"Can. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2018.11.1105_bib0054","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/(SICI)1097-4679(199901)55:1<135::AID-JCLP14>3.0.CO;2-8","article-title":"Initial validation of the voris cocaine craving scale: a preliminary report","volume":"55","author":"Smelson","year":"1999","journal-title":"J. Clin. Psychol."},{"issue":"6","key":"10.1016\/j.euroneuro.2018.11.1105_bib0055","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/01.jcp.0000245562.99036.92","article-title":"Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use","volume":"26","author":"Smelson","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2018.11.1105_bib0056","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.jcp.0000194624.07611.5e","article-title":"The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report","volume":"26","author":"Smelson","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2018.11.1105_bib0057","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2007.11.034","article-title":"The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study","volume":"100","author":"Swartz","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0058","doi-asserted-by":"crossref","unstructured":"Temmingh, H.S., Williams, T., Siegfried, N., Stein, D.J., 2018. Risperidone Versus Other Antipsychotics for People with Severe Mental Illness and Co-Occurring Substance Misuse. The Cochrane Database of Systematic Reviews 1, CD011057. 10.1002\/14651858.CD011057.pub2.","DOI":"10.1002\/14651858.CD011057.pub2"},{"issue":"12","key":"10.1016\/j.euroneuro.2018.11.1105_bib0059","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.4088\/JCP.v63n1214c","article-title":"Olanzapine treatment for patients with schizophrenia and cocaine abuse","volume":"63","author":"Tsuang","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2018.11.1105_bib0060","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/070674370805300610","article-title":"Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial","volume":"53","author":"van Nimwegen","year":"2008","journal-title":"Can. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2018.11.1105_bib0061","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/aje\/kwf043","article-title":"Cannabis use and psychosis: a longitudinal population-based study","volume":"156","author":"van Os","year":"2002","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.euroneuro.2018.11.1105_bib0062","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/schbul\/23.2.215","article-title":"Pharmacotherapy of schizophrenia patients with comorbid substance abuse","volume":"23","author":"Wilkins","year":"1997","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.euroneuro.2018.11.1105_bib0063","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00115-007-2310-4","article-title":"Pharmakotherapie bei schizophrenie und komorbider substanzst\u00f6rung. Eine systematische Ubersicht","volume":"79","author":"Wobrock","year":"2008","journal-title":"Nervenarzt"},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0064","series-title":"Mental Health: New Understanding, New Hope","first-page":"178","year":"2002"},{"key":"10.1016\/j.euroneuro.2018.11.1105_bib0065","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1745-6215-10-46","article-title":"Randomized trials published in some Chinese journals: how many are randomized?","volume":"10","author":"Wu","year":"2009","journal-title":"Trials"},{"issue":"7374","key":"10.1016\/j.euroneuro.2018.11.1105_bib0066","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/bmj.325.7374.1199","article-title":"Self-reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study","volume":"325","author":"Zammit","year":"2002","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.euroneuro.2018.11.1105_bib0067","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2215-0366(17)30270-5","article-title":"Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses","volume":"4","author":"Zhu","year":"2017","journal-title":"The Lancet Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18319667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18319667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:51:54Z","timestamp":1760377914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X18319667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0924977X18319667"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.11.1105","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.11.1105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}